BOSTON, Massachusetts — Swan EndoSurgical has appointed Erik Todd as its Chief Executive Officer, bringing in a seasoned leader with more than 25 years of experience in surgical robotics, endoscopy, and next-generation medtech innovation.
Todd joins the company after a long tenure at Stryker Corporation, where he most recently served as Vice President and General Manager of the Robotics and Enabling Technologies division. His background includes scaling advanced robotic platforms, building global engineering organizations, and driving development across minimally invasive surgery and digital and AI-enabled technologies.
Swan EndoSurgical, backed by Revival Healthcare Capital and Olympus Corporation, is developing a fully integrated flexible endoluminal robotic platform aimed at transforming complex gastrointestinal interventions.
“Erik is an accomplished and respected leader in surgical robotics,” said Justin Ballotta, Managing Director at Revival Healthcare Capital and Head of Post-Investment Value Creation. “With a proven track record of scaling sophisticated robotics platforms from concept through commercialization, Erik brings a global perspective, strategic rigor, and a deep appreciation for clinical needs making him the ideal leader for Swan.”
“The appointment of Erik to Swan EndoSurgical as the CEO marks a pivotal step in advancing our shared vision for endoluminal robotics,” said Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus Corporation. “Together, we are committed to transforming gastrointestinal care through breakthrough robotics, empowering physicians, and delivering safer, less invasive solutions for patients everywhere.”
“I am excited to join Swan EndoSurgical and help advance endoluminal surgery,” said Erik Todd, Chief Executive Officer. “Building on the foundation created by Swan, Revival, and Olympus, we can address unmet needs in advanced GI interventions using robotics, visualization, and flexible access. I look forward to collaborating with Olympus, health care professionals, and our teams to develop, deliver, and scale meaningful innovations for patients around the world.”
